Compare Citius Pharmaceuticals Inc (CTXR) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Corning Incorporated — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while Corning Incorporated trades at $167.26 (market cap $137.12B). The key difference: Corning Incorporated is far larger — about 6852.6× Citius Pharmaceuticals Inc's market cap, and Corning Incorporated pays a 0.7% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GLW | |
|---|---|---|
Market Cap | $20.01M | $137.12B |
Sector | Health | Technology |
52-Week High | $1.82 | $255.79 |
52-Week Low | $0.48 | $64.52 |
Enterprise Value | $16.23M | $144.00B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
GLW trades at $166.95, up 5.84% in the last session, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.78, beating expectations, driven by 17% YoY core sales growth from optical and AI data center demand. Valuation ratios are elevated, with a P/E of 73.36 and P/S of 8.23, while profitability improved with a net income margin of 11.2% in 2025.
The outlook is supported by AI infrastructure growth and analyst optimism, with a consensus price target of $193.33 implying 16% upside. Risks include premium valuation sensitivity and execution challenges in scaling solar and optical segments. Cash flow is projected to turn positive in 2026, but debt-to-asset ratio remains elevated at 27.67%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
